Compare NNNN & KRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNNN | KRP |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | Germany | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | N/A | 2017 |
| Metric | NNNN | KRP |
|---|---|---|
| Price | $16.79 | $14.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.33 |
| AVG Volume (30 Days) | 21.2K | ★ 801.1K |
| Earning Date | 04-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 10.25% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $333,830,000.00 |
| Revenue This Year | N/A | $6.88 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $10.50 | $11.31 |
| 52 Week High | $55.65 | $15.80 |
| Indicator | NNNN | KRP |
|---|---|---|
| Relative Strength Index (RSI) | 33.36 | 42.93 |
| Support Level | $14.66 | $14.10 |
| Resistance Level | $31.12 | $14.95 |
| Average True Range (ATR) | 3.11 | 0.28 |
| MACD | -0.97 | -0.08 |
| Stochastic Oscillator | 9.95 | 10.26 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.